XSHE
000989
Market cap1.10bUSD
Oct 09, Last price
8.91CNY
1D
2.41%
1Q
9.19%
Jan 2017
-58.96%
IPO
-20.47%
Name
Jiuzhitang Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiuzhitang Co., Ltd. is a Chinese pharmaceutical company specializing in the development and distribution of traditional Chinese, chemical, biological, and health-related medicinal products. Its product portfolio addresses a wide array of health concerns. For instance, cardiovascular and cerebrovascular conditions are treated with offerings like shuxuetong injections, Angong Niuhuang Wan, Danxi granules, and Gastrodia Uncaria. Gynecological issues are targeted by Guizhi Fuling pills, Buxue Shengru granules, and other hemostasis and analgesic preparations. Respiratory ailments can be managed with Schicon, while digestive disorders benefit from products such as Jiaqi Ganzian granules, Jianwei Yuyang tablets, Jienchang Ning, and Chidan yellowing products. Furthermore, the company supplies a comprehensive range of over-the-counter (OTC) medications. These non-prescription drugs support areas including qi and blood nourishment, cardiovascular and cerebrovascular health, urinary system function, pediatric care, women's health, musculoskeletal wellness, respiratory relief, dermatological conditions, nervous system support, ENT treatments, digestive aid, and even tumor-related concerns. Established in Beijing, China, in 1999, Jiuzhitang Co., Ltd. maintains its headquarters there.
Key people
Lifeng Wang
Chairman of the Board · since 2025
Lubao Zhou
Chief Financial Officer · since 2024
Zhenguo Li
Vice Chairman of the Board, General Manager · since 2024
Yansong Gao
Deputy General Manager · since 2024
Chunfeng Liu
Deputy General Manager · since 2024
Yongsheng Wu
Deputy General Manager · since 2020
Liangbin Zhang
Deputy General Manager · since 2024
Chenxiao Han
Secretary of the Board · since 2020
Jinfeng Bo
Director · since 2023
Lianbin Sun
Director · since 2024
Guangyuan Sun
Chairman of the Board · since 2024
Yonghui Wang
Director · since 2022
Qiang Wu
Director · since 2025
Zhongfei Yu
Director · since 2025
Yanjing Chen
Independent Director · since 2024
Independent Director · since 2024
Quanguo Zhang
Independent Director · since 2024
Headquarters & legal address
长沙市高新区桐梓坡西路339号
长沙市, HN 410000
CN
长沙市, HN 410000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||